IGF1RHC

Targeting IGF-1 receptor in liver cancer with focus on its mechanistic role in transcription and its interaction with the cell cycle machinery

 Coordinatore KAROLINSKA INSTITUTET 

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Kristina
Cognome: Geiger
Email: send email
Telefono: 46851775878
Fax: 46851770690

 Nazionalità Coordinatore Sweden [SE]
 Totale costo 0 €
 EC contributo 236˙351 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-IIF-2008
 Funding Scheme MC-IIF
 Anno di inizio 2010
 Periodo (anno-mese-giorno) 2010-03-31   -   2012-03-30

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET

 Organization address address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177

contact info
Titolo: Ms.
Nome: Kristina
Cognome: Geiger
Email: send email
Telefono: 46851775878
Fax: 46851770690

SE (STOCKHOLM) coordinator 236˙351.44

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

cancer    affects    genes    cells    hcc    receptor    transcription    tumor    therapeutic    cyclolignan    ppp    cell    studied    cycle    igf    mice   

 Obiettivo del progetto (Objective)

'The insulin-like growth factor-1 receptor (IGF-1R) is a cell surface receptor kinase being vastly expressed in malignant tissues and plays crucial roles in growth and survival of cancer cells. Targeting IGF-1R is pharmaceutically today a very attractive concept. Larsson’s group at KI has contributed extensively to the current knowledge about IGF-1R and demonstrated that the cyclolignan PPP inhibits IGF-1R signaling. An oral IGF-1R inhibitor of cyclolignan chemistry is presently studied in patients with advanced cancer. Recently, they found that IGF-1R is SUMOylated, translocated to the nucleus, where it affects transcription. This is a novel and original function for IGF-1R and one of the goals of this proposal is to further study whether it is limited to tumor cells. In such case, these findings will be a breakthrough and the foundation for further development of specific therapeutic targeting of cancer. Here we aim to study two mechanistic aspects of IGF-1R: (1) its role as a transcription factor in tumor cells, (2) its interaction with the cell cycle machinery, as ultimate regulators of cell division. Hepatocellular carcinoma (HCC) was chosen as it has a very poor prognosis and a high mortality due to absence of efficient treatments. It is one of Egypt’s national health priorities and its incidence is increasing in Europe. Three experimental models will be used : HCC cell lines in which SUMOylation, nuclear translocation of IGF-1R and, which genes it transcriptionally activates will be studied, We will induce HCC in knockout mice lacking Cdk2 and p27, generated by Aleem to study how IGF-1R interacts with loss of these cell cycle proteins, and how its inhibition by PPP affects development and progression of HCC. Mouse Embryo Fibroblasts isolated from these mice will also be used for cell cycle analysis. We anticipate that IGF-1R modulates transcription of genes relevant to tumor growth leading to development of more specific therapeutic tools against liver cancer'

Altri progetti dello stesso programma (FP7-PEOPLE)

COSMOLOGY FROM QG (2014)

What quantum gravity teaches us about the origin of the universe: Extension of early universe cosmology by using non-perturbative quantum gravity

Read More  

INTERFERENCE (2008)

Interference effects in inner-shell excitation of diatomic molecules studied by polarization analysis of fluorescence from valence-ionized states

Read More  

SNISEB (2014)

SINGLE NANOPARTICLE IMPACT STUDIES: THE DIRECT OBSERVATION OF ELECTROCHEMICAL BEHAVIOUR AT THE NANOSCALE

Read More